Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

Antibody therapy is a validated treatment approach for several malignancies. All currently clinically applied therapeutic antibodies (Abs) are of the IgG isotype. However, not all patients respond to this therapy and relapses can occur. IgA represents an alternative isotype for antibody therapy that...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:MAbs
Huvudupphovsmän: Meyer, Saskia, Nederend, Maaike, Jansen, J.H. Marco, Reiding, Karli R., Jacobino, Shamir R., Meeldijk, Jan, Bovenschen, Niels, Wuhrer, Manfred, Valerius, Thomas, Ubink, Ruud, Boross, Peter, Rouwendal, Gerard, Leusen, Jeanette H.W.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Taylor & Francis 2015
Ämnen:
Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966554/
https://ncbi.nlm.nih.gov/pubmed/26466856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1106658
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk